XR IMMERSIVE Aktie

 

  Vancouver, BC – TheNewswire - December 2, 2025 – XR Immersive Technologies Inc. (CSE: VRAI, OTC: FNTTF, FSE: 79W0) (“XR” or the “Company”) is providing a corporate update following the appointment of Shafin Diamond Tejani as Special Advisor, originally announced on October 9, 2025. Since the appointment, the Company has focused on three core priorities: (1) completing all outstanding financial filings, (2) advancing commercialization of its health-related digital twin technology, and (3) progressing through the British Columbia Securities Commission (BCSC) continuous disclosure review and advancing initiatives to restructure outstanding debt to strengthen the balance sheet. Financial Filings Completed XR confirms that the following filings are being submitted today (December 2, 2025): 2024 audited annual financial statements   2024 MDA and related certifications   Q1 2025 interim financial statements and MD   Q2 2025 interim financial statements and MD   Q3 2025 interim financial s...

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL XR IMMERSIVE TECH INC. 79W CA98383L2030 BAW/UFN...

Instrument ID [17561997] (79W - CA98383L2030) suspended...

Vancouver, British Columbia – January 21, 2025 – TheNewswire – XR Immersive Tech Inc. (“Immersive Tech” or the “Company”) (CSE: VRAI) (FSE: 79W) (OTCQB: FNTTF) is pleased to announce the acquisition of Continuous Glucose Monitoring (CGM) technology from InsulinQ. This strategic acquisition marks a significant expansion of Immersive Tech's long-standing presence in the healthcare sector and supports the Company's commitment to providing accessible and user-friendly solutions for diabetes management. Strategic Expansion into Healthcare XR Immersive Tech has been actively involved in the healthcare industry since 2016, working with leading organizations such as Bayer and the US Food and Drug Administration (FDA). These collaborations have enabled the Company to apply its advanced immersive technologies to address critical healthcare challenges. The acquisition of InsulinQ's CGM technology represents a natural evolution of Immersive Tech's strategy to diversify its portfolio and leverage its...